The BioLight unit will follow the study's participants in Mexico for 12 months.
Bio-Light Israeli Life Sciences Investments Ltd. (TASE:BOLT) portfolio company IOptima Ltd. has obtained positive results from the first three months of the initial clinical trial for its OT-134 laser device for the non-invasive treatment of Glaucoma. The trial aims to test the safety and effectiveness of the device.
The trial is being conducted in Mexico. 14 patients, who were candidates for surgical treatments for glaucoma, are participating in the trial. One patient was removed from the trial after failing to fulfill the trial procedures. IOptima reports that all the patients achieved a reduction in the pressure in the eye to below the target level, and were also able to reduce the quantity of medication needed to keep the disease in check. The device was shown to be safe for all the patients.
IOptima will follow the study's participants in Mexico for 12 months.
The company notes that 67 million people suffer from glaucoma worldwide and it is the second leading cause of blindness. Medication therapy often fails because of low patient compliance. Early surgical intervention is sometimes more effective than surgery performed after many years of drug therapy and the availability of a safe surgical procedure is expected to increase the number of surgical interventions.
Published by Globes [online], Israel business news - www.globes-online.com - on May 28, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008